Media Centre
Latest press releases
-
Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia
-
Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia
-
Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer
-
Enhertu approved in the US for the treatment of patients with previously treated HER2-positive advanced gastric cancer
-
Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Kim Blomley
Director Global Media Relations (Oncology)
+44 7385 367659
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
